Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Herrscher

Allergy & Immunology Plano, TX Medical Doctor

NPI 1568425700 CMS profile 298101

3600 Communications Pkwy, Suite 675, Plano, TX 75093

Open in the dashboard

General payments

$20,458

398 records reported · program years 2019–2025

Research payments

$13,068

Paid to them · 16 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$23,861 paid to institutions, not to them · program year 2022

Through program year 2025, Richard Herrscher of Plano, TX is reported in the CMS Open Payments database as having received $20,458 across 398 general payments and $13,068 in research payments paid to them. Separately, studies naming them as principal investigator received $23,861 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 87th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,701 86
2024 General $1,034 44
2023 General $1,256 46
2023 Research $13,068 16
2022 General $10,914 50
2021 General $1,366 60
2020 General $1,099 53
2019 General $1,088 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Herrscher
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Richard Herrscher were reported at $3,701. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Richard Herrscher Allergy & Immunology median Middle half National median
2019 $1,088 $594 $163–$1,512 $163
2020 $1,099 $426 $106–$1,233 $114
2021 $1,366 $638 $157–$1,708 $132
2022 $10,914 $790 $205–$1,961 $149
2023 $1,256 $852 $220–$2,147 $160
2024 $1,034 $865 $203–$2,267 $164
2025 $3,701 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ADMA BioManufacturing LLC $10,793 26 payments
  2. Blueprint Medicines Corporation $2,078 13 payments
  3. AstraZeneca Pharmaceuticals LP $1,029 52 payments
  4. GlaxoSmithKline, LLC. $829 42 payments
  5. Amgen Inc. $502 25 payments
  6. Novartis Pharmaceuticals Corporation $501 24 payments
  7. Pharming Healthcare, Inc. $467 18 payments
  8. Octapharma USA, Inc. $431 9 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $374 17 payments
  10. Pfizer Inc. $335 21 payments
  11. Other $3,119 151 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,938 377 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,525 2 payments
  3. Travel and Lodging $3,900 2 payments
  4. Honoraria $1,523 1 payment
  5. Education $306 9 payments
  6. Consulting Fee $266 7 payments
Products named General payments · program years 2019–2025
  1. NUCALA $476 26 payments
  2. AYVAKIT $409 10 payments
  3. CUVITRU $397 19 payments
  4. FASENRA Respiratory $363 16 payments
  5. RUCONEST $363 14 payments
  6. CUTAQUIG $325 5 payments
  7. FASENRA Respiratory $320 18 payments
  8. DUPIXENT $310 15 payments
  9. TEZSPIRE $258 14 payments
  10. ALVESCO $255 15 payments
  11. Other $5,328 257 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. ADMA BioManufacturing LLC $13,068 16 payments

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

453

Median for Internal Medicine: 777

Drug cost

$134,137

Median for Internal Medicine: $73,373

Branded share of claims

33.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 22 $82,520
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 22 $19,118
Breo Ellipta Fluticasone/Vilanterol Brand 13 $7,448
Airsupra Albuterol Sulfate/Budesonide Brand 14 $7,037
Alvesco Ciclesonide Brand 13 $5,155
Symbicort Budesonide/Formoterol Fumarate Brand 13 $4,364
Epinephrine Generic 14 $2,309
Albuterol Sulfate Hfa Albuterol Sulfate Brand 43 $1,641
Montelukast Sodium Generic 100 $1,133
Ventolin Hfa Albuterol Sulfate Brand 13 $925

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$3,413,193

Of which drugs: $3,329,732

Medicare patients

152

Average age 72

Services billed

69,070

99 women, 53 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 46%
Ischemic heart disease 29%
Depression 27%
COPD 24%
Osteoporosis 24%
Diabetes 22%
Chronic kidney disease 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 21 19,590 $585,163
Injection, benralizumab, 1 mg J0517 Office 12 1,560 $204,186

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AYVAKIT
  • Blueprint Medicines Corporation $258
$258 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $94
  • Genentech USA, Inc. $33
$127 — 19,590
RUCONEST
  • Pharming Healthcare, Inc. $93
$93 — —
TEZSPIRE
  • Amgen Inc. $49
  • AstraZeneca Pharmaceuticals LP $33
$82 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $65
$65 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

414 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record